Non-small-cell lung carcinoma

Presents Positive Safety and Efficacy Data from the Completed Phase 1 Dose Escalation Cohort of ICT01 plus Pembrolizumab in the EVICTION Trial at ESMO Congress 2022

Retrieved on: 
Saturday, September 10, 2022
Olive, HNSCC, Acute myeloid leukemia, Head, Population, Goal, Oncology, Cancer, Bladder cancer, CD8, Malignancy, European Society for Medical Oncology, ESMO, Safety, Neoplasm, CPI, Doctor of Philosophy, CNRS, Infection, MD, Degenerative disease, INSERM, T, Large-cell lung carcinoma, AACR, Antibody, Pembrolizumab, Lung, Hematological Cancer Research Investment and Education Act, Tumor microenvironment, Immunology, Group C, NSCLC, PD-1, EMSO, Pancreatic cancer, Congress, Phase, Therapy, Non-small-cell lung carcinoma, Follicular lymphoma, Breast, SITC, Research, Prostate, NK, Clinical trial, Mab, Part, Colorectal cancer, Acute leukemia, Group B, Melanoma, Ovary, Vaccine, Pharmaceutical industry, Medical imaging, Butyrophilin, subfamily 1, member A1, Patient

EVICTION is an open-label Phase I/IIa study evaluating ImChecks lead antibody ICT01 as a monotherapy in both solid tumor and hematological cancers, and in combination with pembrolizumab in solid tumors.

Key Points: 
  • EVICTION is an open-label Phase I/IIa study evaluating ImChecks lead antibody ICT01 as a monotherapy in both solid tumor and hematological cancers, and in combination with pembrolizumab in solid tumors.
  • The broad antitumor response data suggest that higher baseline circulating 92 T cell levels correlate with better treatment outcomes.
  • The data was presented during the investigational immunotherapy session from 14:45 to 16:15 CEST on Saturday September 10, 2022.
  • Part 2 of the trial is a Phase II cohort expansion study in selected indications as both monotherapy and in combination.

Roche's VENTANA PD-L1 (SP263) Assay receives CE IVD approval to identify patients with locally advanced and metastatic non-small cell lung cancer eligible for Libtayo

Retrieved on: 
Friday, September 9, 2022
Lung cancer, Mortality, Lung, Dow Jones, Regeneron Pharmaceuticals, Cancer, Medication, ALK, View, Large-cell lung carcinoma, Internet, Incidence, Hoffmann-La Roche, Genentech, Phase, Assay, Royal commission, Treatment of lung cancer, Multimedia, RO, PD-1, GlobalData, Medicine, Prevalence, Immunotherapy, News, NSCLC, Pharma, Biomarker, Roche Diagnostics, ROG, Non-small-cell lung carcinoma, CE, PD-L1, European Commission, ROS, Benchmark, Patient, World Health Organization, Medical imaging, Medical device, Uranium, Fine chemical, Cemiplimab, Diagnosis, Chugai Pharmaceutical Co.

This additional approval will allow more patients with locally advanced and metastatic non-small cell lung cancer broader access to the immunotherapy Libtayo.

Key Points: 
  • This additional approval will allow more patients with locally advanced and metastatic non-small cell lung cancer broader access to the immunotherapy Libtayo.
  • This approval gives eligible advanced lung cancer patients access to the immunotherapy Libtayo as a first-line treatment," said Jill German, Head of Pathology Lab at Roche Diagnostics.
  • VENTANA PD-L1 (SP263) Assay is used to detect programmed death ligand-1 (PD-L1) protein in non-small cell lung carcinoma patients.
  • Last month, Roche announced that the VENTANA PD-L1 (SP263) Assay received CE label expansion in non-small cell lung cancer as a companion diagnostic for Tecentriq (atezolizumab).

Roche's VENTANA PD-L1 (SP263) Assay receives CE IVD approval to identify patients with locally advanced and metastatic non-small cell lung cancer eligible for Libtayo

Retrieved on: 
Friday, September 9, 2022
Lung cancer, Mortality, Lung, Dow Jones, Regeneron Pharmaceuticals, Cancer, Medication, ALK, Large-cell lung carcinoma, Internet, Incidence, Hoffmann-La Roche, Genentech, Phase, Assay, Royal commission, Treatment of lung cancer, RO, PD-1, GlobalData, Medicine, Prevalence, Immunotherapy, News, NSCLC, Pharma, Biomarker, Roche Diagnostics, ROG, Non-small-cell lung carcinoma, CE, PD-L1, European Commission, ROS, Benchmark, Patient, World Health Organization, Medical imaging, Medical device, Uranium, Fine chemical, Cemiplimab, Diagnosis, Chugai Pharmaceutical Co.

This additional approval will allow more patients with locally advanced and metastatic non-small cell lung cancer broader access to the immunotherapy Libtayo.

Key Points: 
  • This additional approval will allow more patients with locally advanced and metastatic non-small cell lung cancer broader access to the immunotherapy Libtayo.
  • This approval gives eligible advanced lung cancer patients access to the immunotherapy Libtayo as a first-line treatment," said Jill German, Head of Pathology Lab at Roche Diagnostics.
  • VENTANA PD-L1 (SP263) Assay is used to detect programmed death ligand-1 (PD-L1) protein in non-small cell lung carcinoma patients.
  • Last month, Roche announced that the VENTANA PD-L1 (SP263) Assay received CE label expansion in non-small cell lung cancer as a companion diagnostic for Tecentriq (atezolizumab).

Kiyatec to Sponsor and Exhibit at the Virtual American Brain Tumor Association 2022 National Conference September 9-10, 2022

Retrieved on: 
Wednesday, September 7, 2022
Biotechnology, Technology, Health, General Health, Pharmaceutical, Oncology, Other Science, Other Technology, Research, Science, Clinical Trials, Breast, 3D, Caregiver, Research, Survivor, American Brain Tumor Association, LinkedIn, Conference, Company, Twitter, Neoplasm, Ovarian cancer, Non-small-cell lung carcinoma, Patient, National Conference, Medical imaging

Kiyatec, the leader in clinically correlated, published functional precision oncology evidence today announced the company is sponsoring and exhibiting at the virtual American Brain Tumor Association 2022 National Conference September 9-10, 2022.

Key Points: 
  • Kiyatec, the leader in clinically correlated, published functional precision oncology evidence today announced the company is sponsoring and exhibiting at the virtual American Brain Tumor Association 2022 National Conference September 9-10, 2022.
  • Details regarding this event can be found here: https://www.abta.org/national-conference-2022/
    The ABTA National Conference is the only advocacy-led educational meeting designed specifically for patients, survivors and caregivers that brings together the entire brain tumor community.
  • Held annually, thousands of attendees learn from the nations leading experts about the latest advances in brain tumor research, treatment and care.
  • Leveraging its innovative 3D cell culture technology platform for both clinical and pre-clinical use, Kiyatec recently introduced its first commercial assay in the US, 3D Predict Glioma.

Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors

Retrieved on: 
Wednesday, September 7, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, RECIST, PR, Security (finance), COVID-19, Triple-negative breast cancer, Diarrhea, Safety, Program, Peripheral neuropathy, Immunohistochemistry, Bicycle, Therapy, NASDAQ, Anemia, Rash, Head, Incidence, Toxic leukoencephalopathy, Thromboxane A2, Phase, Neck, Cancer research, Forward-looking statement, SEC, Esophageal cancer, Drug development, Ovary, U.S. Securities and Exchange Commission, IHC, ORR, Biotechnology, Neoplasm, Cancer, ADC, Investor, Risk, Clinical trial, BTC, Ovarian cancer, Private Securities Litigation Reform Act, MT1-MMP, Non-small-cell lung carcinoma, Review, CD137, Patient, DCR, Pharmaceutical industry, Vaccine, Medical imaging

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced Phase I dose escalation top-line results from its Phase I/II trial of BT5528, a BTC targeting EphA2, in patients with advanced solid tumors.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced Phase I dose escalation top-line results from its Phase I/II trial of BT5528, a BTC targeting EphA2, in patients with advanced solid tumors.
  • The therapeutic profile from the dose escalation portion of the Phase I/II trial of BT5528 in patients with late-line disease suggests both differentiated safety and promising activity, most notably in ovarian and urothelial cancers, said Dominic Smethurst, Chief Medical Officer of Bicycle Therapeutics.
  • BT5528, a BTC targeting EphA2, a target for which prior antibody-based approaches have been unsuccessful, has demonstrated anti-tumor activity and differentiated tolerability.
  • Bicycle has established an RP2D dose (6.5mg/m2 every other week) and is enrolling ongoing expansion cohorts.

Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors That Kill Glioblastoma Cells and Melanoma Cells, and Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90%, Announced by Ocean Biomedical, Inc. and Aesther Healthcare

Retrieved on: 
Tuesday, September 6, 2022
Lung cancer, COVID-19, Human, CEO, Safety, Biomedicine, Research, Antibody, Culture, Lung, NEW, PD-1, Mergers and acquisitions, GLOBE, 100,000, Risk, PD-L1, Metastasis, Patient, Inflammation, University, CTLA4, Cancer, Survival, Ageing, Protein, SEC, Immunology, FDA, Communication, Transaction, Cell death, Tripura Merger Agreement, Secondary research, Lists of diseases, Brain, GBM, Pulmonary fibrosis, NASDAQ, Glioblastoma, Skin cancer, PTEN, Investment, Probability, NSCLC, Neoplasm, Melanoma, Non-small-cell lung carcinoma, Acquisition, Growth, HIV disease progression rates, SPAC, XV, Ix, Mouse, PD, Therapy, Failure, Malaria, Apoptosis, Biology, Forward-looking statement, Medical device, Medical imaging, Vaccine, Pharmaceutical industry, Risk management, CHI3L1, Medicine, R.I

PROVIDENCE, R.I. and NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ocean Biomedical and Aesther Healthcare Acquisition Corp. (“Aesther”) (NASDAQ: AEHA) announced today the discovery of bispecific antibodies that target Chitinase 3-like-1 and immune checkpoint inhibitors, killing glioblastoma cells and melanoma cells, and blocking the metastasis of malignant melanoma cells to the lung by over 90%. Glioblastoma multiforme (GBM) is a deadly type of brain tumor and 5-year survival is just 8% for those aged 45-54. About 25% of GBM patients are not actively treated due to rapid disease progression. Malignant melanoma, the most serious skin cancer, can metastasize to other organs. Once it has spread to other organs it is difficult to treat. Metastatic melanoma (Stage IV) has 22.5% five year survival. Non-small cell lung cancer (NSCLC) is a major unmet medical need that accounts for 85% of pulmonary malignancies and effects approximately 450,000 individuals. In greater than 50% of affected patients the tumors are diagnosed at advanced stages with metastatic spread that precludes curative surgical resection.

Key Points: 
  • Antibodies that target ICPI such as PD-1, PD-L1 and CTLA4 have been generated which have therapeutic efficacy in NSCLC and other tumors.
  • The impressive ability of our bispecific antibodies to control primary and metastatic lung cancer in murine experimental modeling systems is discussed below.
  • In the coculture system, critical immune regulating cells called T cells were placed in culture with cancer cells.
  • Neither of Ocean Biomedical or Aesther gives any assurance that Ocean Biomedical or Aesther, or the combined company, will achieve its expectations.

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Daiichi Sankyo and AstraZeneca’s ENHERTU® for Treatment of NSCLC Patients With Activating HER2 Mutations

Retrieved on: 
Friday, August 12, 2022
Research, FDA, Genetics, Professional Services, Health, Data Analytics, Pharmaceutical, Science, Oncology, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, ADC, ERBB2, Gene, Medicare, The New England Journal of Medicine, Cancer, Non-small-cell lung carcinoma, Medicine, GH, HER2, Security (finance), American Society of Clinical Oncology, Annual report, Analysis, National Comprehensive Cancer Network, Blood, Result, NSCLC, Neoplasm, Health, Patient, CDC, LDT, Twitter, NGS, Journal of the National Comprehensive Cancer Network, SNV calling from NGS data, Financial condition report, Daiichi Sankyo, News, AstraZeneca, LinkedIn, Oncology, Cdx, Helmy Eltoukhy, Food, Pharmaceutical industry, Vaccine, Medical imaging, Uranium

We are proud to offer our Guardant360 CDx liquid biopsy as a companion diagnostic so that patients can access comprehensive genomic profiling to see if they are eligible to receive this therapy.

Key Points: 
  • We are proud to offer our Guardant360 CDx liquid biopsy as a companion diagnostic so that patients can access comprehensive genomic profiling to see if they are eligible to receive this therapy.
  • Guardant360 CDx covers all genes recommended by the National Comprehensive Cancer Network, including those most relevant to clinical care and NSCLC treatment guidelines.
  • Guardant Health has commercially launched Guardant360, Guardant360 CDx, Guardant360 TissueNext, Guardant360 Response, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal for early-stage cancer patients.
  • The Guardant Health screening portfolio, including the Shield test, aims to address the needs of individuals eligible for cancer screening.

Merus Announces Financial Results for the Second Quarter and Provides Business Update

Retrieved on: 
Monday, August 8, 2022
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Betta, Trial of the century, Prostate cancer, ASCO, RECIST, Zeno, GLOBE, ORR, Annual general meeting, Clinical trial, NRG1, Non-small-cell lung carcinoma, IND, Achievement, HER2, Biologics license application, Cancer, Income, NSCLC, Pancreas, Patient, Neck, Pancreatic cancer, Program, HER3, Castration, Safety, Collaboration, Peto, Research, Chlorine, Head, AstraZeneca, Afatinib, Agreement, Food, Pharmaceutical industry, Health insurance, Dietary supplement, Cryptocurrency, Meru Networks, Osimertinib, Lilly, Incyte

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the second quarter that ended June 30, 2022 and provided a business update.

Key Points: 
  • We believe the favorable safety profile of Zeno may also allow for future, potential benefit in combination with other cancer therapies.
  • Details of the eNRGy trial can be found at www.ClinicalTrials.gov and Merus trial website at www.nrg1.com ,or by calling 1-833-NRG-1234.
  • As of June 30, 2022, Merus had $396.8 million cash and cash equivalents sufficient to fund company operations beyond 2024.
  • We ended the second quarter with cash, cash equivalents and marketable securities of $396.8 million compared to $430.7 million at December 31, 2021.

EQRx Announces Late-Breaking Oral Presentation of Final Progression-Free Survival Results from Phase 3 Trial of Sugemalimab in Stage III Non-small Cell Lung Cancer at IASLC 2022 World Conference on Lung Cancer

Retrieved on: 
Sunday, August 7, 2022
FDA, Woman, Regulation of tobacco by the U.S. Food and Drug Administration, Lung cancer, National Medical Products Administration, HIV disease progression rates, FAQ, Forward-looking statement, GLOBE, Food, Technology, SEC, Non-small-cell lung carcinoma, PD-L1, Annual report, NSCLC, Man, Patient, Review, Instagram, Chemoradiotherapy, Large-cell lung carcinoma, Twitter, WCLC, Multimodality, NMPA, Safety, Stomach, Adenocarcinoma, Lung, International Association, Â, Social media, Esophageal cancer, Squamous cell carcinoma, PFS, Nasdaq, MD, LinkedIn, Progression-free survival, Conference, Response evaluation criteria in solid tumors, Adult, Disease, Catalog, Pharmaceutical industry, Greater China

Median PFS was 10.5 months for sugemalimab and 6.2 months for placebo (hazard ratio [HR]=0.65, 95% CI 0.500.84, P=0.0012).

Key Points: 
  • Median PFS was 10.5 months for sugemalimab and 6.2 months for placebo (hazard ratio [HR]=0.65, 95% CI 0.500.84, P=0.0012).
  • Data for overall survival, a secondary endpoint, were encouraging but immature at the time of the analysis.
  • The safety profile for sugemalimab was consistent with previously reported results, and no new safety signals were identified within the follow-up period.
  • *
    Lung cancer is the leading cause of cancer death for men and women worldwide.2 Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85% of all lung cancer diagnoses.

Lung Cancer Diagnostics Global Market Report 2022: Increasing Prevalence and Incidence of Lung Cancer to Push the Demand for Early Diagnoses - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 4, 2022
Health, Oncology, Precision medicine, Diagnosis, D, COVID-19, Smoker, Nucleic acid thermodynamics, CAGR, Lung cancer, Prevalence, Growth, SCLC, Biomarker, Disease, Non-small-cell lung carcinoma, Blood, Investment, Squamous cell carcinoma, NSCLC, DNA, Exosome, Incidence, Biopsy, US, Awareness, Medical imaging

The "Lung Cancer Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Lung Cancer Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The disease is categorized into Small-cell Lung Cancer (SCLC) and Non-small cell lung cancer (NSCLC), with the latter constituting for about 80-85% of cases.
  • Early detection of lung cancer, for both NSCLC and SCLC, is taking increased precedence globally which in turn spurs demand for lung cancer diagnostics.
  • The United States represents the largest regional market for Lung Cancer Diagnostics, and is projected to reach US$843.4 Million by 2026.